Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France
Identifieur interne : 001688 ( Main/Exploration ); précédent : 001687; suivant : 001689Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France
Auteurs : Emmanuelle Bondon-Guitton [France] ; Santiago Perez-Lloret [France] ; Haleh Bagheri [France] ; Christine Brefel [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-10.
Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Age Factors, Antipsychotic Agents (adverse effects), Female, France, Humans, Longitudinal Studies, Male, Parkinson Disease, Secondary (chemically induced), Pharmacovigilance, Retrospective Studies, Time Factors, adverse drug reactions, antipsychotics, calcium channel blockers, dopaminergic antagonists, drug safety, neuroleptics, parkinsonism, pharmacovigilance.
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- geographic : France.
- chemically induced : Parkinson Disease, Secondary.
- Age Factors, Female, Humans, Longitudinal Studies, Male, Pharmacovigilance, Retrospective Studies, Time Factors.
Abstract
Besides antipsychotics, several drugs can induce parkinsonism. We review spontaneous notifications of drug‐induced or ‐worsened parkinsonism to a French regional pharmacovigilance center between 1993 and 2009. During these 17 years, 20,855 adverse drug reactions have been reported, including 155 (0.7%) cases of drug‐induced or ‐worsened parkinsonism. Most of the notifications have involved aged patients (48% between 60 and 79 years) and females (60%). “Seriousness” was found in 43.9% of cases. Worsening of parkinsonism occurred in 28 patients suffering from idiopathic Parkinson's disease. Sixty‐nine percent of drug‐induced or ‐worsened parkinsonism cases were observed during the first 3 months after introduction of the “suspect” drug (involving mainly central dopaminergic antagonists). A second peak (20%) was found 12 months after drug introduction (mainly caused by calcium channel blockers). The most frequently reported parkinsonian symptom was rigidity (78.7%). The three cardinal symptoms were found in 37.4% of notifications. Evolution was favorable (after partial or complete withdrawal of suspect drug[s]) in 88.7% of cases. Among the 261 suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found. Three notifications were the result of pharmacokinetic interactions. We found that drug‐induced or ‐worsened parkinsonism is an often “serious,” but reversible, adverse drug reaction. It occurred more frequently between 60 and 79 years. Rigidity was the most frequently reported symptom. Approximately 50% of drug‐induced or ‐worsened parkinsonism cases spontaneously reported were related to drugs other than antipsychotics. Drug‐induced or ‐worsened parkinsonism can also be explained by pharmacokinetic drug interactions. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23828
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000608
- to stream Istex, to step Curation: 000608
- to stream Istex, to step Checkpoint: 000421
- to stream PubMed, to step Corpus: 001121
- to stream PubMed, to step Curation: 001121
- to stream PubMed, to step Checkpoint: 001363
- to stream Ncbi, to step Merge: 003308
- to stream Ncbi, to step Curation: 003308
- to stream Ncbi, to step Checkpoint: 003308
- to stream Main, to step Merge: 001742
- to stream Main, to step Curation: 001688
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title>
<author><name sortKey="Bondon Uitton, Emmanuelle" sort="Bondon Uitton, Emmanuelle" uniqKey="Bondon Uitton E" first="Emmanuelle" last="Bondon-Guitton">Emmanuelle Bondon-Guitton</name>
</author>
<author><name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
</author>
<author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name>
</author>
<author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:14DB4B8B72EEA12B30E737B0D05908027E7AA6C7</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23828</idno>
<idno type="url">https://api.istex.fr/document/14DB4B8B72EEA12B30E737B0D05908027E7AA6C7/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000608</idno>
<idno type="wicri:Area/Istex/Curation">000608</idno>
<idno type="wicri:Area/Istex/Checkpoint">000421</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Bondon Uitton E:drug:induced:parkinsonism</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21674626</idno>
<idno type="wicri:Area/PubMed/Corpus">001121</idno>
<idno type="wicri:Area/PubMed/Curation">001121</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001363</idno>
<idno type="wicri:Area/Ncbi/Merge">003308</idno>
<idno type="wicri:Area/Ncbi/Curation">003308</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003308</idno>
<idno type="wicri:Area/Main/Merge">001742</idno>
<idno type="wicri:Area/Main/Curation">001688</idno>
<idno type="wicri:Area/Main/Exploration">001688</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title>
<author><name sortKey="Bondon Uitton, Emmanuelle" sort="Bondon Uitton, Emmanuelle" uniqKey="Bondon Uitton E" first="Emmanuelle" last="Bondon-Guitton">Emmanuelle Bondon-Guitton</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-10">2011-10</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="2226">2226</biblScope>
<biblScope unit="page" to="2231">2231</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">14DB4B8B72EEA12B30E737B0D05908027E7AA6C7</idno>
<idno type="DOI">10.1002/mds.23828</idno>
<idno type="ArticleID">MDS23828</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Female</term>
<term>France</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Pharmacovigilance</term>
<term>Retrospective Studies</term>
<term>Time Factors</term>
<term>adverse drug reactions</term>
<term>antipsychotics</term>
<term>calcium channel blockers</term>
<term>dopaminergic antagonists</term>
<term>drug safety</term>
<term>neuroleptics</term>
<term>parkinsonism</term>
<term>pharmacovigilance</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Pharmacovigilance</term>
<term>Retrospective Studies</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Besides antipsychotics, several drugs can induce parkinsonism. We review spontaneous notifications of drug‐induced or ‐worsened parkinsonism to a French regional pharmacovigilance center between 1993 and 2009. During these 17 years, 20,855 adverse drug reactions have been reported, including 155 (0.7%) cases of drug‐induced or ‐worsened parkinsonism. Most of the notifications have involved aged patients (48% between 60 and 79 years) and females (60%). “Seriousness” was found in 43.9% of cases. Worsening of parkinsonism occurred in 28 patients suffering from idiopathic Parkinson's disease. Sixty‐nine percent of drug‐induced or ‐worsened parkinsonism cases were observed during the first 3 months after introduction of the “suspect” drug (involving mainly central dopaminergic antagonists). A second peak (20%) was found 12 months after drug introduction (mainly caused by calcium channel blockers). The most frequently reported parkinsonian symptom was rigidity (78.7%). The three cardinal symptoms were found in 37.4% of notifications. Evolution was favorable (after partial or complete withdrawal of suspect drug[s]) in 88.7% of cases. Among the 261 suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found. Three notifications were the result of pharmacokinetic interactions. We found that drug‐induced or ‐worsened parkinsonism is an often “serious,” but reversible, adverse drug reaction. It occurred more frequently between 60 and 79 years. Rigidity was the most frequently reported symptom. Approximately 50% of drug‐induced or ‐worsened parkinsonism cases spontaneously reported were related to drugs other than antipsychotics. Drug‐induced or ‐worsened parkinsonism can also be explained by pharmacokinetic drug interactions. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
<orgName><li>Université Toulouse III - Paul Sabatier</li>
<li>Université de Toulouse</li>
</orgName>
</list>
<tree><country name="France"><noRegion><name sortKey="Bondon Uitton, Emmanuelle" sort="Bondon Uitton, Emmanuelle" uniqKey="Bondon Uitton E" first="Emmanuelle" last="Bondon-Guitton">Emmanuelle Bondon-Guitton</name>
</noRegion>
<name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name>
<name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name>
<name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
<name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001688 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001688 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:14DB4B8B72EEA12B30E737B0D05908027E7AA6C7 |texte= Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France }}
This area was generated with Dilib version V0.6.23. |